Comparison of four breast cancer tests can help oncologists and patients to choose the most appropriate test when considering chemotherapy.
‘All of the four commercially available tests can accurately predict the recurrence of breast cancer up to 10 years.’
The analysis, published in JAMA Oncology, funded by Cancer Research UK and involving co-authors at the Institute of Cancer Research, compares four common prognostic tests for breast cancer, and finds that not all are able to accurately predict whether the cancer will return after five years. This could be limiting clinicians' abilities to advise patients on whether chemotherapy or preventive medication, in the form of endocrine therapy1, should be taken. Lead author Dr Ivana Sestak from Queen Mary's Wolfson Institute of Preventive Medicine said: "This is the first time that anyone has directly compared the prognostic performance of these four common commercially-available tests. This gives clinicians and oncologists the opportunity to review all the results and decide upon the test they want to use for their breast cancer patients.
"If a woman is deemed high risk of recurrence by any test, the benefit of chemotherapy is greatest. In contrast, if a women is deemed low risk then endocrine therapy alone will be sufficient and patients could forego chemotherapy and its side effects.
"Being able to accurately predict the risk of breast cancer recurrence is even more important now that we are in an era where women are prescribed preventive endocrine therapy for many years. If we were better able to accurately assess a woman's long-term risk, then some women may be able to end their endocrine therapy after five years. But for those deemed high risk of a late recurrence, continuing their endocrine therapy would be a valuable option."
The team directly compared four prognostic tests for breast cancer in the same patient cohort of 774 postmenopausal women with the most common type of breast cancer - oestrogen-receptor positive (ER+), HER2-negative. They did this by compiling test results from the original tumour biopsies and then looked at whether the patients' cancers later returned.
Advertisement
Angelina Jolie, An Inspiration for Women to Undergo Breast Cancer Tests
The hollywood actress has announced that she will remove her breasts as she has been tested positive for breast cancer by a genetic test.
The hollywood actress has announced that she will remove her breasts as she has been tested positive for breast cancer by a genetic test.
All major practice guidelines endorse some of these prognostic tests to aid risk prediction in a range of breast cancer patients.
Advertisement
Angelina Jolie�s Decision to Make Her Double Mastectomy Public Helps Double Breast Cancer Tests in UK
Hollywood star Angelina Jolie’s stance to come out with her decision to undergo double mastectomy to prevent breast cancer has helped.
Hollywood star Angelina Jolie’s stance to come out with her decision to undergo double mastectomy to prevent breast cancer has helped.
Out of the four tests, the US Food & Drug Administration has approved ROR and the European Society for Medical Oncology recommends the use of Oncotype, ROR and EPclin.
The team found that all of the four commercially available tests are providing substantial prognostic value for women with node-negative disease2, by being able to predict the recurrence of breast cancer up to 10 years after the start of their treatment (with ROR, BCI, and EPclin performing better than the older Oncotype test).
However, one important critical time period to consider is years 5-10 after the start of treatment, since over 50 percent of women with ER+ breast cancer develop a recurrence after five years. BCI, ROR, and EPclin were found to be the most accurate for stratifying women into low or high risk of recurrence after five years in patients with node-negative disease.
For women with node-positive disease2 only those tests (ROR and EPclin) that incorporated clinical information (e.g. tumour size and the number of positive lymph nodes a woman has), as well as gene expression levels, provided substantial prognostic value.
The study is limited in that the results are only applicable for chemotherapy-free and postmenopausal women.
Source-Eurekalert
